Evidence map›Paper›PMID 34759712›Full record

ArticleJournal of central nervous system disease2021

The Effect of Body Mass Index on Brain Volume and Cognitive Function in Relapsing-Remitting Multiple sclerosis: A CombiRx Secondary Analysis.

Aliza Bitton Ben-Zacharia, Malvin N Janal, Abraham A Brody, Jerry Wolinsky, Fred Lublin, Gary Cutter

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Journal of central nervous system disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00211887 (A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients With Relapsing-Remitting Multiple Sclerosis), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00211887 phase3completednot on this map

A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients With Relapsing-Remitting Multiple Sclerosis (CombiRx)

TypeinterventionalSponsorFred LublinRan2005 to 2013Enrolled1,008ConditionsRelapsing Remitting Multiple SclerosisArmsInterferon beta 1-a, glatiramer acetate, placebo
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Aliza Bitton Ben-ZachariaMount Sinai Hospital, New York, NY, USA.ORCID https://orcid.org/0000-0002-3174-8244
Malvin N JanalDepartment of Epidemiology and Health Promotion, NYU College of Dentistry, New York, NY, USA.
Abraham A BrodyRory Meyers College of Nursing, NYU, New York, NY, USA.
Jerry WolinskyMcGovern Medical School, University of Texas, Huston, TX, USA.
Fred LublinDepartment of Medicine, Mount Sinai Icahn School of Medicine, New York, NY, USA.
Gary CutterSchool of Public Health, UAB, Birmingham, AL, USA.
Alabama Department of Public Health · USHunter College · USIcahn School of Medicine at Mount Sinai · USYork University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultiple sclerosis (MS) is an autoimmune disease leading to physical, emotional and cognitive disability. High body mass index (BMI) may impact cognitive function and brain volume in MS. Yet, there is paucity of evidence addressing the impact of BMI on cognitive function and brain volume in MS.

objectivesThe purpose of this study was to examine the effects of BMI on normal appearing brain volume and cognitive function in patients with relapsing-remitting MS.

methodsA secondary data analysis of the NIH CombiRx study was conducted. Multivariate regression and mixed model analyses were executed to analyze the effect of BMI on brain volume and cognitive function.

resultsThe mean baseline age of the 768 participants was 38.2(SD = 9.4) years. 73% were female and 88.8% were Caucasian. The mean BMI was 28.8 kg/m

conclusionBMI did not show an effect on cognitive function and brain volume among MS patients. Although there is increased interest in the effects of modifiable factors on the course of MS, the effects of BMI on brain volume and cognitive function are debatable and warrant further research.ClinicalTrials.gov NCT00211887.

Indexed as

brain volumecognitionMRIMultiple sclerosisoutcome measurementsRRMS

Identifiers

PMID34759712
PMCPMC8573693
OpenAlexW3211534074

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.